Every 10-Q that Prime Medicine, Inc. (PRME) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PRME and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRME filings page.
Prime Medicine, Inc. reported collaboration revenue of $1.15 million in the quarter ended June 30, 2026 and a net loss of $42.1 million, or $0.24 per share. For the first half of 2026, revenue was $2.0 million and net loss narrowed to $91.2 million from $104.5 million a year earlier, mainly due to lower research and development spending.
Cash, cash equivalents and short‑term investments totaled $95.1 million as of June 30, 2026, with stockholders’ equity at $39.8 million. Management concludes that substantial doubt exists about the company’s ability to continue as a going concern over the next 12 months without additional financing and highlights its at‑the‑market equity program and other potential transactions, while expecting existing cash to fund operations into 2027.
Prime Medicine advanced its Prime Editing pipeline: regulators cleared a CTA in New Zealand and an FDA IND for Wilson disease candidate PM577a, and an IND/CTA filing for AATD candidate PM647 is planned for the third quarter of 2026. CGD program PM359 received FDA RMAT designation, with a planned BLA submission in the first half of 2027. An arbitration tribunal also confirmed PM647 is within the company’s “Field” under its Beam collaboration and denied Beam’s requests for damages and injunctive relief.
Prime Medicine (PRME) filed its Q3 2025 10‑Q, highlighting a development‑stage profile with modest collaboration revenue and ongoing investment in programs. Total revenue was $1.2 million in the quarter, while the net loss was $50.6 million or $(0.32) per share. Year to date, revenue reached $3.8 million with a net loss of $155.1 million.
Operating expenses reflected pipeline progress and footprint expansion: R&D was $44.0 million and G&A was $11.2 million in Q3. Cash used in operations for the first nine months was $125.3 million. The balance sheet shows $71.4 million in cash and cash equivalents and $137.0 million in short‑term investments, totaling $213.3 million in cash, cash equivalents, and investments as of September 30, 2025. Management states this is sufficient to fund operations for at least twelve months from issuance.
In August 2025, the company completed a public offering of 43.7 million shares at $3.30 per share for $138.4 million in net proceeds. As of September 30, 2025, 180,309,471 shares were outstanding. Prime Medicine also recorded an $18.0 million research funding liability tied to external funding arrangements.
Prime Medicine (PRME) – Q2 2025 10-Q Snapshot
- Revenue: $1.1 m collaboration revenue (none in Q2 24); H1 revenue $2.6 m (+335% YoY).
- Expenses: R&D $41.4 m (-4% YoY); G&A $13.1 m (+4%). Total op-ex $54.5 m; loss from operations $53.4 m.
- Net loss: $52.6 m or $0.41/sh vs $55.3 m ($0.46) prior-year; H1 loss $104.5 m.
- Liquidity: Cash & cash equivalents $53.8 m (-70% YTD); investments $48.0 m; total liquid resources $101.8 m. Post-period Aug-25 equity raise added net $138.2 m, giving management >12-month runway.
- Balance sheet shifts: Right-of-use assets up to $120.2 m and non-current lease liabilities to $112.5 m following new Cambridge & Watertown facilities. Stockholders’ equity fell to $60.9 m (vs $153.1 m YE24) on continuing losses.
- Strategic updates: Focus pivots to in-vivo liver programs (Wilson’s, AATD) targeting INDs 1H-26; additional $24 m funding commitment from Cystic Fibrosis Foundation, incl. $6 m equity.
- Risks: Ongoing arbitration with Beam Therapeutics over AATD program could impose damages or halt development; high cash burn (~$90 m H1) and dilution from stock issuance remain concerns.
Management believes current cash plus August offering funds operations through at least Q3 26 while programs advance toward first clinical filings.